Clinical Trial

Efgartigimod in IVIG Dependent Myasthenia Gravis Patients

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is an open label, single center, prospective, 26 weeks study with descriptive analysis where IVIG is replaced by efgartigimod therapy. MG-ADL and MGQOL evaluations will occur weekly throughout the study to week 26.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-01-03; most recent amendment 2025-07-25.
Status change: Not Yet Recruiting → Recruiting 2025-02-06
Trial Details
NCT Number NCT06765161
Lead Sponsor Clinique Neuro-Outaouais
Collaborators: argenx
Conditions Myasthaenia Gravis
Enrollment 30 participants
Start Date 2025-02-06
Primary Completion 2027-01-06 (estimated)
Study Completion 2027-01-06 (estimated)
Updated on ClinicalTrials.gov 2025-07-29